JUN 08, 2016 02:00 PM PDT

Alteration of "Programmed Death Ligand" Promotes Cancer Metastasis

WRITTEN BY: Kara Marker
There’s a protein that signals the immune system not to kill certain cells. This action could be preventing autoimmune disease, or it could be harnessed by cancer cells to inhibit the immune system when it should be fighting back. A new study from Kyoto University in Japan uncovered genetic alterations to the protein that increase production in favor of growing tumors, and they plan to counteract these changes to prevent cancer growth.

Image credit: Kyoto University
 
The protein at the center of this study is called programmed-death ligand 1, or PD-L1. The genetic mutation that occurs and promotes cancer growth disrupts normal structure of the gene’s 3’ untranslated region of the gene the codes for the PD-L1 protein. The researchers plan to continue investigating these structural changes to understand how cancer cells can grow uncontrollably with the immune system inhibited by PD-L1 activity.
 
There are very effective treatment options using antibodies that target either PD-L1 or its receptor, PD-1, that exists on the surface of immune cells like T lymphocytes. However, these therapies are just as expensive as they are effective. In order to create treatment options that are both effective and affordable, the researchers from Kyoto University set out to identify cancer biomarkers to pinpoint which patients would respond especially well to immune checkpoint inhibitor drugs like PD-L1 targeting antibodies.
 
Of the 27 percent of patients with adult T cell leukemia or lymphoma who had genetic alterations of the 3’ untranslated region of the PD-L1 gene, the researchers used next-generation genetic sequencing data in attempt to identify the source of alteration. The researchers also sequenced data from over ten thousand samples from the Cancer Genome Atlas, finding similar alterations in other cancer types, including malignant lymphoma, stomach cancer, and cervical cancer.
 
The Cancer Genome Atlas is a collaboration between the National Cancer Institute and the National Human Genome Research Institute dedicated to providing comprehensive maps of key genomic changes in over 30 types of cancer.
 
The researchers were able to generate the same genetic alterations of the 3’ untranslated region of the PD-L1 gene in human and mouse cells using CRISPR-Cas9, a genome editing system using short palindromic repeats that target DNA based on sequence complementarity. Just like their previous findings, these cells had an elevated level of PD-L1 expression, and cancer cells were able to evade an immune attack.
 
On tap next for this research group is to test the structural genetic alteration as a genetic marker for cancer in a phase II clinical trial.
 
“Once we confirm the significance of these genetic alterations, it’ll be a game changer for immunotherapy in cancer,” said senior author of the study, Seishi Ogawa, PhD.
 

 
Sources: Kyoto University, New England Biolabs, Nature, Cancer Genome Atlas
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 18, 2018
Immunology
JUL 18, 2018
Immunotherapy Increases Survival of Melanoma Brain Metastases Patients
Use of Checkpoint Blockade Immunotherapy increases survival rates in Melanoma Brain Metastases patients, with a 4-year survival rate increase from 11.1% to 28.1%...
AUG 04, 2018
Immunology
AUG 04, 2018
Infant's Innate Immune Response
An infant's innate immune response develops from fetus to birth, but it may not be as "immature" as previously thought....
AUG 20, 2018
Immunology
AUG 20, 2018
Photosensitivity Linked to Immune Cell Dysfunction
The Langerhans cells of the immune system activate cytokines essential for skin protection when exposed to UV that is functional in photosensitive individuals....
AUG 27, 2018
Immunology
AUG 27, 2018
Undiscovered Tunnels from Bone Marrow To Brain
Newly discovered tunnels connect bone marrow of the skull directly to lining of the brain to allow for quick access of immune cells to brain damaged tissues....
OCT 10, 2018
Microbiology
OCT 10, 2018
It's Time for Your Annual Flu Shot
After last year's flu season killed around 80,000 people, the CDC is trying to get the word out about the flu vaccine....
NOV 13, 2018
Immunology
NOV 13, 2018
Yin & Yang: The Duality of Cancer-Associated Fibroblasts in Pancreatic Cancer
Pancreatic Cancer is a devastating disease. Fifty-five thousand new patients were diagnosed this year in the United States (1). It is painful and usua...
Loading Comments...